Business Wire

Engle Martin & Associates, LLC Announces Acquisition of EIMC, LLC

17.4.2023 15:00:00 EEST | Business Wire | Press release

Share

Engle Martin & Associates, LLC ("Engle Martin"), a market-leading independent loss adjusting and claims management provider, announced today that it has acquired EIMC, LLC (“EIMC”), a leading global provider of ocean marine, risk management, claims investigation, and subrogation services based in Jersey City, New Jersey and London, England.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230417005197/en/

Founded in 1968, EIMC serves clients across the entire marine global supply chain with 50+ years of expertise in providing the full continuum of assessments, risk mitigation, and claim resolution solutions within marine cargo, stock throughout, hull & machinery, and fine art & specie. EIMC operates in 15 office locations strategically positioned in the United States and the United Kingdom. The organization works with a broad group of clients in all major international insurance markets and is also the Lloyd’s Agent for multiple locations in the United States. Since its inception, EIMC has been recognized by major international insurers and numerous insurance associations as a premier provider of marine insurance risk management and claims services.

This acquisition expands Engle Martin’s global footprint and diversifies its service portfolio by providing clients with a full suite of ocean marine services. This acquisition also provides EIMC an extensive back-office infrastructure, innovative technology solutions, and growth opportunities for team members. EIMC has a remarkable history within the maritime community that has resulted in distinctive and long-lasting relationships with its clients and carrier partners. EIMC’s leadership team will remain in place and will maintain operational oversight of their portfolio.

When asked about the acquisition, Jay Campbell, Executive Vice President of Strategy & Organizational Growth of Engle Martin, said “We are excited to continue growing and investing in our business. The acquisition expands our service capabilities in the ocean marine & technical risk services arena with an organization that is well-aligned with our culture and approach to business. We will continue to provide our clients with the same service, quality, and capabilities they have come to expect from our team, with a complementary service that allows us to respond to our customers in a holistic manner.”

Tiina Ruhlandt, Managing Director of EIMC, said “We are delighted that Engle Martin appreciates the value of our organization; and we are confident and excited that our combined expertise will have a positive impact on our continued growth and success. We believe that this partnership is an excellent extension of Engle Martin’s long-term business strategy, and we are thrilled to have a partner who shares our principles and respects the culture which has driven our success.”

About Engle Martin

Engle Martin is a market-leading independent loss adjusting and claims management provider. Engle Martin has a comprehensive business philosophy: to provide the best insurance claim adjustment results in the industry, present the most talented claims professionals, foster an innovative and professional leadership team, and develop client-focused solutions. The firm provides a comprehensive line of service offerings including commercial property, casualty, specialty marine and transportation, appraisal/umpire, specialty audits, carrier outsourcing, and claims management services. For details about industries served and services offered by Engle Martin, visit EngleMartin.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Dominique Enriquez
Marketing Director
+1 678.553.3872
denriquez@englemartin.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye